» Articles » PMID: 33904966

Memory Enhancement by Multidomain Group Cognitive Training in Patients with Parkinson's Disease and Mild Cognitive Impairment: Long-term Effects of a Multicenter Randomized Controlled Trial

Abstract

Background: Meta-analyses indicate positive effects of cognitive training (CT) in patients with Parkinson's disease (PD), however, most previous studies had small sample sizes and did not evaluate long-term follow-up. Therefore, a multicenter randomized controlled, single-blinded trial (Train-ParC study) was conducted to examine CT effects in PD patients with mild cognitive impairment (PD-MCI). Immediately after CT, an enhancement of executive functions was demonstrated. Here, we present the long-term results 6 and 12 months after CT.

Methods: At baseline, 64 PD-MCI patients were randomized to a multidomain CT group (n = 33) or to a low-intensity physical activity training control group (PT) (n = 31). Both interventions included 90 min training sessions twice a week for 6 weeks. 54 patients completed the 6 months (CT: n = 28, PT: n = 26) and 49 patients the 12 months follow-up assessment (CT: n = 25, PT: n = 24). Primary study outcomes were memory and executive functioning composite scores. Mixed repeated measures ANOVAs, post-hoc t tests and multiple regression analyses were conducted.

Results: We found a significant time x group interaction effect for the memory composite score (p = 0.006, η = 0.214), but not for the executive composite score (p = 0.967, η = 0.002). Post-hoc t tests revealed significant verbal and nonverbal memory improvements from pre-intervention to 6 months, but not to 12 months follow-up assessment in the CT group. No significant predictors were found for predicting memory improvement after CT.

Conclusions: This study provides Class 1 evidence that multidomain CT enhances memory functioning in PD-MCI after 6 months but not after 12 months, whereas executive functioning did not change in the long-term.

Clinical Trial Registration: German Clinical Trials Register (ID: DRKS00010186), 21.3.2016 (The study registration is outlined as retrospective due to an administrative delay. The first patient was enrolled three months after the registration process was started. A formal confirmation of this process from the German Clinical Trials Register can be obtained from the authors.).

Citing Articles

Effectiveness and Feasibility of Nonpharmacological Interventions for People With Parkinson's Disease and Cognitive Impairment on Patient-Centred Outcomes: Systematic Review and Meta-Analysis.

Pigott J, Armstrong M, Tabassum N, Davies N, Schrag A Parkinsons Dis. 2024; 2024:3654652.

PMID: 39588065 PMC: 11588407. DOI: 10.1155/2024/3654652.


Cognitive behavioral therapy approaches to the improvement of mental health in Parkinson's disease patients: a systematic review and meta-analysis.

Wu X, Shi M, Lian Y, Zhang H BMC Neurol. 2024; 24(1):352.

PMID: 39300337 PMC: 11411832. DOI: 10.1186/s12883-024-03859-x.


Resting state EEG as biomarker of cognitive training and physical activity's joint effect in Parkinson's patients with mild cognitive impairment.

Trenado C, Trauberg P, Elben S, Dimenshteyn K, Folkerts A, Witt K Neurol Res Pract. 2023; 5(1):46.

PMID: 37705108 PMC: 10500911. DOI: 10.1186/s42466-023-00273-5.


Efficacy of non-pharmacological interventions for depression in individuals with Parkinson's disease: A systematic review and network meta-analysis.

Wang Y, Sun X, Li F, Li Q, Jin Y Front Aging Neurosci. 2022; 14:1050715.

PMID: 36438007 PMC: 9691406. DOI: 10.3389/fnagi.2022.1050715.

References
1.
Monastero R, Cicero C, Baschi R, Davi M, Luca A, Restivo V . Mild cognitive impairment in Parkinson's disease: the Parkinson's disease cognitive study (PACOS). J Neurol. 2018; 265(5):1050-1058. DOI: 10.1007/s00415-018-8800-4. View

2.
Wiesli D, Meyer A, Fuhr P, Gschwandtner U . Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease. Dement Geriatr Cogn Dis Extra. 2017; 7(3):297-308. PMC: 5662998. DOI: 10.1159/000478849. View

3.
de Lau L, Verbaan D, Marinus J, van Hilten J . Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism Relat Disord. 2014; 20(6):613-6. DOI: 10.1016/j.parkreldis.2014.02.030. View

4.
Rolinski M, Fox C, Maidment I, McShane R . Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012; (3):CD006504. PMC: 8985413. DOI: 10.1002/14651858.CD006504.pub2. View

5.
McShane R, Westby M, Roberts E, Minakaran N, Schneider L, Farrimond L . Memantine for dementia. Cochrane Database Syst Rev. 2019; 3:CD003154. PMC: 6425228. DOI: 10.1002/14651858.CD003154.pub6. View